

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
11 April 2002 (11.04.2002)

PCT

(10) International Publication Number  
**WO 02/28385 A1**

- (51) International Patent Classification<sup>7</sup>: **A61K 31/19**, 31/195
- (21) International Application Number: PCT/US01/30835
- (22) International Filing Date: 2 October 2001 (02.10.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/237,444 3 October 2000 (03.10.2000) US
- (71) Applicant (*for all designated States except US*):  
**PHILADELPHIA, HEALTH AND EDUCATION CORPORATION** [US/US]; Broad and Vine Streets, Philadelphia, PA 19102 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **JAMESON, Bradford, A.** [US/US]; 3210 Fairway Road, Huntingdon Valley, PA 19006 (US). **TRETIAKOVA, Anna** [RU/US]; 401 S. Quince Street, 1R, Philadelphia, PA 19147 (US).
- (74) Agents: **LICATA, Jane, Massey et al.**; Licata & Tyrell P.C., 66 E. Main Street, Marlton, NJ 08053 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
- *with international search report*
  - *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: COMPOSITIONS AND METHODS FOR DESIGNING AND USING COMPOSITIONS WHICH INHIBIT ACTIVATED HELPER T CELLS

(57) Abstract: Compositions containing compounds and methods for identifying and designing compounds with a basic pharmacophore which disrupts a primary activation signal in Helper T cells and induces death or anergy of activated cells are provided. Also provided are methods of using these compositions to inhibit CD4 activity and undesired immune responses which result therefrom.

WO 02/28385 A1

**Compositions and Methods for Designing and Using  
Compositions which Inhibit Activated Helper T Cells**

**Introduction**

This invention was supported in part by funds from  
5 the U.S. government (NIH Grant No. NS37726) and the U.S.  
government may therefore have certain rights in the  
invention

**Background of the Invention**

Autoimmune conditions including, but not limited to,  
10 Multiple Sclerosis, systemic lupus erythematosus,  
rheumatoid arthritis and Crohn's Disease are characterized  
by an aberrant constellation of events resulting in clonal  
activation of CD-4 dependent T cells and, ultimately, a  
pathologic inflammatory response. Thus, while the  
15 etiologies of many autoimmune diseases are unknown, CD4-  
positive Helper T cells appear to be crucial mediators in  
both disease onset and progression (Hutchings et al. 1993).

CD4-positive Helper T cells are predominantly  
produced in the thymus where they undergo both positive and  
20 negative selection. Each Helper T cell produced in this  
organ is unique by virtue of its polymorphic T Cell Antigen  
Receptor (TCR) that is matched to the resident Major  
Histocompatibility Complex II (MHC II) proteins. The  
mature cells that emerge are highly diverse and selected as  
25 discriminators of self versus non-self. As these cells  
migrate to the periphery, they become responsive to peptide  
antigens presented within the groove of the MHC II  
heterodimer on Antigen Presenting Cells (APCs) (Brown et al.  
1993). Under normal circumstances, only the Helper T cells  
30 bearing a TCR that appropriately fits with the foreign

-2-

antigen-bearing APC will become inactivated. The rest of the subset of CD4-positive cells remains quiescent. The activated T cell clonally proliferates, secreting growth factors and cytokines, and aids in the mounting of both  
5 humoral as well as cytotoxic immune responses.

Accordingly, attempts have been made to treat the symptoms of autoimmune diseases including, but not limited to, Multiple Sclerosis, rheumatoid arthritis, systemic lupus erythematosus and Crohn's Disease, through use of  
10 compounds which inhibit CD4.


For example, U.S. Patent 5,958,882 discloses compounds which mimic the surface presented by one of five distinct lateral domains of CD4. The compounds disclosed in this patent are relatively short peptides comprising 20,  
15 or more preferably 10 to 15 amino acids derived from specific regions of CD4. These compounds are suggested to be useful in treating individuals suffering from or susceptible to conditions characterized by an undesired immune response.

20 Large synthetic analogs of the CDR 3-like domain of CD4 have also been established to inhibit CD4-dependent responses (Jameson et al. 1994). These large peptides lack biologically reproducible effects, however, as there is a large variation in batch-to-batch activities.

25

#### Summary of the Invention

An object of the present invention is to provide compositions comprising a basic pharmacophore of Formula (I)



-3-

for use in inhibiting CD4 activity.

Another object of the present invention is to provide methods for designing and identifying new compounds expected to inhibit CD4 activity wherein the new compounds  
5 comprise the basic pharmacophore of Formula (I).


Another object of the present invention is to provide a method for inhibiting CD4 activity in cells or tissues comprising contacting cells or tissues with a composition comprising the basic pharmacophore of Formula (I).

10 Yet another object of the present invention is to provide a method for alleviating undesired immune responses in an individual suffering from or susceptible to undesired immune responses comprising administering to the individual a composition comprising the basic pharmacophore of Formula  
15 (I).


#### Detailed Description of the Invention

The CD4 protein has multiple protein contacts within the activation clusters of Helper T cells. Using the crystal structures of the human CD4 protein as a template  
20 for rational design process, a basic pharmacophore has now been identified which is responsible for the CD-4 inhibitory activity of various analogs. By pharmacophore it is meant the smallest unit that retains reproducible, biological activity. The basic pharmacophore of the  
25 present invention comprises an amide group at one end, followed by a glutamic acid side chain, a nitrogen, a carbonyl, a methyl group and an R group. Modification of any of these elements except the R group was found to result in a loss of activity. The structure of this basic  
30 pharmacophore is depicted in Formula (I):

-4-




wherein R is selected from the group consisting of a straight chain alkyl, preferably 1 to 7 carbons in length, an alkyl followed by an aromatic ring preferably ranging in size from 4 to 9 carbons, or a structure of Formula (II):



As demonstrated herein, small molecular weight (MW<500) compounds designed to comprise this pharmacophore mimic the surface of CD4 thereby disrupting the primary activation signal generated through the T cell activation cluster in the Helper T cells and inducing programmed cell death and/or anergy in the activated cells. Analogs containing this pharmacophore induce clonal deletion or anergy only in the activated sets of T cells without effecting the resting repertoire of cells needed to mount desired immune responses.


Three compounds comprising the basic pharmacophore of the present invention and different R groups were prepared. These compounds are depicted herein as Compound 1, 2 and 3.

Compound 1:




-5-

Compound 2:



Compound 3:



The ability of each of these compounds to inhibit CD4  
5 activity was demonstrated in an assay for mixed lymphocyte  
reaction (MLR) inhibition. These analogs showed greater  
inhibitory activity than the original analog disclosed by  
Jameson et al. 1994. In addition, Compound 1, 2 and 3  
have a molecular weight of approximately 5 times less than  
10 the original analog disclosed by Jameson et al. 1994 and  
possess highly consistent biological activities. Of these,  
Compound 1 with the single methyl group attachment  
demonstrated the highest CD4 inhibitory activity.

The CD4 inhibitory activity of compounds comprising  
15 the basic pharmacophore of the present invention was  
confirmed in an *in vivo* murine model in accordance with  
procedures set forth by Tretiakova et al. (Nature  
Biotechnology September 2000 18:984-988). This model  
employed the use of C57/BL mice to generate a well-  
20 characterized CD4-dependent response to a murine  
retrovirus, MuLV. The CD-4 dependent response is used to  
drive the Cytotoxic T Lymphocyte (CTL) response. It is  
well established that inhibition of the Helper T cell  
response abolishes the CTL response. Accordingly, animals

-6-

of this model were administered a single intravenous bolus injection of Compound 3 after the Helper T cell response had been initially generated and then once again after re-challenge with the MuLV. After three weeks, the animals  
5 were sacrificed and the CTLs were assayed for their ability to recognize the MuLV-env protein, also referred to as target-specific killing response, and for their ability to respond to novel stimuli, also referred to as allogeneic stimulation. Only mice treated with Compound 3 showed  
10 inhibition of the virus target-specific response while still maintaining a robust allogeneic response.

Thus, provided in the present invention are compositions comprising compounds with the basic pharmacophore of Formula (I). As demonstrated herein, such  
15 compounds disrupt the primary activation signal in Helper T cells and induce death or anergy of activated cells both *in vitro* and *in vivo*. Also provided in the present invention are methods for producing other new compounds with these capabilities through synthesis of compounds with this basic  
20 pharmacophore. Methods for synthesizing such compounds can be performed routinely by those of skill in the art in similar fashion to the chemical syntheses described in Example 1 or other well known methods. In addition, the identification of this basic pharmacophore and its  
25 activities enables one of skill in the art to screen for additional compounds comprising this basic pharmacophore which are also expected to disrupt the primary activation signal in Helper T cells and induce death or anergy of activated cells both *in vitro* and *in vivo*.

30 Compositions comprising a compound with this basic pharmacophore are useful in inhibiting CD4 activity, and in particular undesired CD4 activity such as occurs in autoimmune diseases including, but not limited to, Multiple Sclerosis, Crohn's Disease, rheumatoid arthritis and  
35 systemic lupus erythematosus, as well as other undesired

-7-

immune responses such as occurs in tissue transplant rejection and against gene therapies. Accordingly, the present invention also relates to method for inhibiting CD4 activity in cells or tissues by contacting cells or tissues  
5 with a composition comprising a compound with the basic pharmacophore of Formula (I). In addition, the present invention provides methods for inhibiting an undesired immune response in an individual suffering from or susceptible to undesired immune responses by administering  
10 to the individual a composition comprising a compound with the basic pharmacophore of Formula (I). Doses of compounds to be administered and modes of administrations can be determined routinely by those skill in the art based upon data from assays such as described herein. Acceptable  
15 pharmaceutical formulations for these compounds can also be determined routinely by those skill in the art based upon teachings in standard reference texts such as *Remington's Pharmaceutical Sciences*, Mack Publishing Co., Easton, PA, 1985.

20       The following nonlimiting examples are provided to further illustrate the present invention.

#### **EXAMPLES**

##### **Example 1: Synthesis of Compounds 1, 2 and 3**

Using established protocols in solid-phase F-moc  
25 chemistry, various target compounds were synthesized on an Advanced ChemTech 440 MOS synthesis robot. First, Rink Amide MBHA resin (Nova Biochem) was added to each reaction vessel. Next, the resin was activated using dimethyl formamide (Fisher), and then washed using piperidine  
30 (Acros). One of four amino acids was added to each of the reaction vessels such that each filled one-quarter of the vessels. Those amino acids were glutamine, glutamic acid, asparagine, and aspartic acid in the form of f-moc-Gln(trt)-OH (Advanced ChemTech), f-moc-Glu(OtBu)-OH (Nova



-8-

Biochem), f-moc-Asn(trt)-OH (Advanced ChemTech), and f-moc-Asp(OtBu)-OH, respectively. This was carried out in four-fold excess, relative to the resin. The amino acids were linked to the resin using diisopropyl carbodiimide

5 (Fisher), also in four-fold molar excess. The vessels were again washed using piperidine.


The linked amino acids were then activated using dimethyl formamide. The vessels were once again washed using piperidine. One of nine compounds was then added to  
10 each of the four amino acids, yielding thirty-six unique end products. These nine compounds were added in ten-fold excess relative to the activated amino acids, and were linked using diisopropyl carbodiimide, also in ten-fold excess. These compounds were hydrocinnamic acid (Acros),  
15 propionic acid (Aldrich), 5-methoxy-1-indone-3-acetic acid (Aldrich), cyclohexylacetic acid (Aldrich), 2-cyclopentene-1-acetic acid (Aldrich), cyclopentanecarboxylic acid (Fluka), cyclohexanecarboxylic acid (Fluka),  
3-phenylbutyric acid (Fluka), and 2-ethylbutyric acid  
20 (Fluka). The reaction vessels were again washed with piperidine, and then once again with methanol to wash and dry them.

The final products were cleaved from the resin using trifluoroacetic acid (Acros). The trifluoroacetic acid was  
25 removed, and the compounds were dried with a VirTis Sentry lyophilizer. The dried products were finally resolubilized in Hanks Balanced Saline Solution (Sigma) and prepared for *in vitro* testing.


- 9 -

What is Claimed is:

1. A composition comprising a compound with a basic pharmacophore of Formula (I):



5 wherein R is selected from a group consisting of a straight chain alkyl, an alkyl followed by an aromatic ring, or a structure of Formula (II):




2. A method for inhibiting CD4 activity in cells or  
10 tissues comprising contacting cells or tissues with a composition of claim 1.


3. A method for inhibiting an undesired immune response in an individual suffering from or susceptible to undesired immune responses comprising administering to the  
15 individual a composition of claim 1.

4. A method for producing a compound which disrupts a primary activation signal in Helper T cells and induces death or anergy of activated cells comprising synthesizing a compound comprising a basic pharmacophore of Formula (I):


-10-




wherein R is selected from a group consisting of a straight chain alkyl, an alkyl followed by an aromatic ring, or a structure of Formula (II):



- 5            5. A method for identifying compounds which disrupt a primary activation signal in Helper T cells and induce death or anergy of activated cells comprising screening compounds for a basic pharmacophore of Formula (I):



- 10 wherein R is selected from a group consisting of a straight chain alkyl, an alkyl followed by an aromatic ring, or a structure of Formula (II):



-11-

and wherein the presence of this basic pharmacophore in the compound is indicative of the compound being capable of disrupting a primary activation signal in Helper T cells and inducing death or anergy of activated cells.

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/30835

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(7) : A61K 31/19, 31/195  
 US CL : 514/557, 561, 563, 564

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/557, 561, 563, 564

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
 EAST and STN:CAPlus and Registry files

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

| Category *    | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No.    |
|---------------|--|--------------------------|
| X<br>---<br>Y | BRAY, A. M. et al. Simultaneous Multiple Synthesis of Peptide Amides by the Multipin Method. Application of Vapor-Phase Ammonolysis. J. Org. Chem., 1994, Vol. 59, pages 2197-2203, see entire document. | 1, 4, 5<br>-----<br>2, 3 |
| X<br>---<br>Y | FERGUSON, G. et al. The Bacterial Pigment from Pseudomonas lemonnieri. Part 1, J. Chems. Soc., Perkin I, 1980, pages 1782-1787, see entire document.   | 1,4,5<br>-----<br>2,3    |
| X<br>---<br>Y | WO 90/14429 A1 (NOVO NORDISK A/S) 29 November 1990 (29.11.90), especially pages 8, 20-21.  | 1, 4<br>-----<br>2, 3, 5 |
| A             | TRETIAKOVA, A. P. et al. Rational design of cytotoxid T-cell inhibitors. Nature Biotechnology. September 2000, Vol. 18, pages 984-988.   | 1-5                      |



Further documents are listed in the continuation of Box C.



See patent family annex.

|  |   |     |  |
|--|---|-----|--|
| * Special categories of cited documents: |   | "T" | later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  |
| "A"                                      | document defining the general state of the art which is not considered to be of particular relevance  | "X" | document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone   |
| "E"                                      | earlier application or patent published on or after the international filing date   | "Y" | document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art |
| "L"                                      | document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | "&" | document member of the same patent family  |
| "O"                                      | document referring to an oral disclosure, use, exhibition or other means  |     |  |
| "P"                                      | document published prior to the international filing date but later than the priority date claimed  |     |  |

Date of the actual completion of the international search

12 December 2001 (12.12.2001)

Date of mailing of the international search report

21 FEB 2002

Name and mailing address of the ISA/US

Commissioner of Patents and Trademarks  
 Box PCT  
 Washington, D.C. 20231

Facsimile No. (703)305-3230

Authorized officer

M.P. Moon

Telephone No. 703-308-0198

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/30835

## C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages                     | Relevant to claim No. |
|------------|--|-----------------------|
| Y          | WO 96/20722 A1 (THOMAS JEFFERSON UNIVERSITY) 11 July 1996 (11.07.96) pages 17-20, see entire document. | 2,3,4                 |